Advertisement

Recent Non-neurogenic Overactive Bladder Trials

  • Luiz Gustavo Oliveira BritoEmail author
  • Luis Guilherme Teixeira dos Santos
Overactive Bladder (U Lee and S Adelstein, Section Editors)
  • 15 Downloads
Part of the following topical collections:
  1. Topical Collection on Overactive Bladder
  2. Topical Collection on Overactive Bladder

Abstract

Purpose of Review

We sought to address the most important trials regarding overactive bladder (OAB) syndrome published in the past 5 years regarding pharmacological treatment and minimally invasive procedures (botulinum toxin A, percutaneous tibial nerve stimulation, and sacral neuromodulation).

Recent Findings

Most of the randomized controlled trials related to OAB are studying anticholinergics and/or beta-adrenergics versus each other or to a placebo-comparator group. Studies have shown stability of using mirabegron and that combination therapy (anticholinergics plus beta-adrenoceptors) seems a good choice for patients with OAB. Percutaneous tibial nerve stimulation needs further studies with comparators to confirm its role. Regarding intra-vesical botulinic toxin or sacral neuromodulation for OAB, both options present good percentages of patient improvement, with no clinically significant difference between them to this moment.

Summary

Despite a growing number of high-quality randomized trials on OAB, further studies are needed comparing different lines of treatment for this disease.

Keywords

Overactive bladder Randomized controlled trials Treatment Review 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21(1):5–26.CrossRefGoogle Scholar
  2. 2.
    Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I. Economic burden of urgency urinary incontinence in the United States: a systematic review. J Manag Care Pharm. 2014;20(2):130–40.Google Scholar
  3. 3.
    Coyne KS, Sexton CC, Vats V, Thompson C, Kopp ZS, Milsom I. National community prevalence of overactive bladder in the United States stratified by sex and age. Urology. 2011;77(5):1081–7.CrossRefGoogle Scholar
  4. 4.
    Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemans JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol. 2012;118(6 Suppl):2455–63.CrossRefGoogle Scholar
  5. 5.
    Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol. 2015;193(5):1572–80.CrossRefGoogle Scholar
  6. 6.
    Rai BP, Cody JP, Alhasso A, Stewart L. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults. Cochrane Database Syst Rev. 2012;12:CD003193.Google Scholar
  7. 7.
    Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. 2012;110(11):1767–74.CrossRefGoogle Scholar
  8. 8.
    Reynolds WS, McPheeters M, Blume J, Surawicz T, Worley K, Wang L, et al. Comparative effectiveness of anticholinergic therapy for overactive bladder: a systematic review and meta-analysis. Obstet Gynecol. 2015;125(6):1423–32.CrossRefGoogle Scholar
  9. 9.
    • Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, et al. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med. 2015;175(3):401–7. This study has stimulated the discussion for further investigation about the association between anticholinergics and dementia. CrossRefGoogle Scholar
  10. 10.
    Chapple CR, Cardozo L, Nitti VW, Siddiqui E, Michel C. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn. 2014;33(1):17–30.CrossRefGoogle Scholar
  11. 11.
    • White WB, Siddiqui E, Tat T, Franks B, Schermer CR. Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. J Am Soc Hypertens. 2018;S1933-1711(18):30241–9.  https://doi.org/10.1016/j.jash.2018.08.001 This study shows a stable cardiovascular profile of mirabegron. Google Scholar
  12. 12.
    • Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballea S, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74:324–33. This review is interesting for the network meta-analysis format and because it compares different arms of treatment. CrossRefGoogle Scholar
  13. 13.
    Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol. 2015;67:577–88.CrossRefGoogle Scholar
  14. 14.
    Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomized double-blind multicenter phase 3b study (BESIDE). Eur Urol. 2016;70(1):136–45.CrossRefGoogle Scholar
  15. 15.
    •• Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;1220(4):562–75. This is the largest RCT sampling comparing combined therapy versus monotherapy in OAB treatment. CrossRefGoogle Scholar
  16. 16.
    Batista JE, Kolbl H, Herschorn S, et al. The efficacy and safety of mirabegron compared with solifenacin in overactive bladder patients dissatisfied with previous antimuscarinic treatment due to lack of efficacy: results of a noninferiority, randomized, phase IIIb trial. Ther Adv Urol. 2015;7:167–79.CrossRefGoogle Scholar
  17. 17.
    Chapple C, Schneider T, Haab F, Sun F, Whelan L, Scholfield D, et al. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial. BJU Int. 2014;114:418–26.Google Scholar
  18. 18.
    Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, et al. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82:313–20.CrossRefGoogle Scholar
  19. 19.
    Khullar V, Amarenco G, Angulo JC, Cambronero J, Høye K, Milsom I, et al. Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283–95.CrossRefGoogle Scholar
  20. 20.
    Kuo HC, Lee KS, Na Y, Sood R, Nakaji S, Kubota Y, et al. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a beta3-adrenoceptor agonist, in patients with overactive bladder in Asia. Neurourol Urodyn. 2015;34:685–92.CrossRefGoogle Scholar
  21. 21.
    Nitti VW, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol. 2013;189:1388–95.CrossRefGoogle Scholar
  22. 22.
    Yamaguchi O, Marui E, Kakizaki H, Homma Y, Igawa Y, Takeda M, et al. Phase III, randomised, double-blind, placebo-controlled study of the beta3-adrenoceptor agonist mirabegron, 50 mg once daily, in Japanese patients with overactive bladder. BJU Int. 2014;113:951–60.CrossRefGoogle Scholar
  23. 23.
    Moossdorff-Steinhauser HF, Berghmans B. Effects of percutaneous tibial nerve stimulation on adult patients with overactive bladder syndrome: a systematic review. Neurourol Urodyn. 2013;32(3):206–14.CrossRefGoogle Scholar
  24. 24.
    Gaziev G, Topazio L, Iacovelli V, et al. Percutaneous tibial nerve stimulation (PTNS) efficacy in the treatment of lower urinary tract dysfunctions: a systematic review. BMC Urol. 2013;13:61.CrossRefGoogle Scholar
  25. 25.
    Vecchioli-Scaldazza C, Morosetti C. Effectiveness and durability of solifenacin versus percutaneous tibial nerve stimulation versus their combination for the treatment of women with overactive bladder syndrome: a randomized controlled study with a follow-up of ten months. Int Braz J Urol. 2018;44(1):10–108.CrossRefGoogle Scholar
  26. 26.
    Scaldazza CV, Morosetti C, Giampieretti R, Lonrezetti R, Baroni M. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study. Int Braz J Urol. 2017;43(1):121–6.CrossRefGoogle Scholar
  27. 27.
    Preyer O, Umerk W, Lami T, Bjelic-Radisic V, Gabriel B, Mittlboeck M, et al. Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;191:51–6.CrossRefGoogle Scholar
  28. 28.
    Mangera A, Apostolidis A, Andersson KE, et al. An updated systematic review and statistical comparison of standardized mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2014;65:981–90.CrossRefGoogle Scholar
  29. 29.
    • Chughtai B, Dunphy C, Lee R, et al. Randomized, double-blind, placebo-controlled pilot study of intradetrusor injections of onabotulinumtoxinA for the treatment of refractory overactive bladder persisting following surgical management of benign prostatic hyperplasia. Can J Urol. 2014;21:7217–21. This is one of the few, well-designed studies comparing botulinum toxin in men with BPH. Google Scholar
  30. 30.
    Nitti VW, Dmochoshki R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol. 2013;189(6):2186–93.CrossRefGoogle Scholar
  31. 31.
    Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomized, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249–56.CrossRefGoogle Scholar
  32. 32.
    Jo JK, Kim KN, Kim DW, Kim YT, Kim JY, Kim JY. The effect of onabutolinumtoxinA according to site of injection in patients with overactive bladder: a systematic review and meta-analysis. World J Urol. 2018;36(2):305–17.CrossRefGoogle Scholar
  33. 33.
    Hassouna MM, Siegel SW, Nyeholt AA, et al. Sacral neuromodulation in the treatment of urgency-frequency symptoms: a multicenter study on efficacy and safety. J Urol. 2000;163:1849–54.CrossRefGoogle Scholar
  34. 34.
    Siegel S, Noblett K, Mangel J, Griebling TL, Sutherland SE, Bird ET, et al. Results of a prospective randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder. Neurourol Urodyn. 2015;34(3):224–30.CrossRefGoogle Scholar
  35. 35.
    Amundsen CL, Richter HE, Menefee SA, Komesu YM, Arya LA, Gregory WT, et al. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316(13):1366–74.CrossRefGoogle Scholar
  36. 36.
    Amundsen CL, Kmoesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, et al. Two-year outcomes of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial. Eur Urol. 2018;74(1):66–73.CrossRefGoogle Scholar
  37. 37.
    Royner ES, Carlson KV, Deal AS, Nair KV, Oakkar EE, Park J, et al. A Prospective, non-intErventional Registry Study of PatiEnts initiating a Course of drug Therapy for overactIVE bladder (PERSPECTIVE): Rationale, design and methodology. Contemp Clin Trials. 2018;70:83–7.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Luiz Gustavo Oliveira Brito
    • 1
    Email author
  • Luis Guilherme Teixeira dos Santos
    • 2
  1. 1.Department of Obstetrics and Gynecology, School of Medical SciencesUniversity of CampinasCampinasBrazil
  2. 2.Hospital Universitario Antonio PedroFluminense Federal UniversityNiteróiBrazil

Personalised recommendations